QualityDipStocks / Health Care · Biotech
Vor Biopharma VOR
Outside our quality screen, so we don’t track its dips. It’s 23% below its 52-week high.
Outside our quality screen, 5% over its Market Value. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- $18.27price +5%
- Off 52-wk high
- −23%
- Risk vs market
- Highbeta 1.76
52-week range 68% of the way from its 52-week low to its high
Price $19.25Market Value $18.27
1 bullish · 5 bearish See why
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
52-wk high: P/E 2.2×; now: P/E 0.9×.
| High | Now | |
|---|---|---|
| Price | $25.10Sep 8 | $19.25 |
| Implied growth | n/a | n/a |
| P/E | 2.2× | 0.9× |
What this means: a lower P/E than at the high means you pay less for each dollar of profit than buyers did then.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for VOR: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much VOR moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings much more than the market, and its own price swings are 8.3× the S&P 500’s.
- Beta vs S&P 500
- 1.76
- Volatility
- 106% vs 13% SPY
- Correlation SPY
- 0.21
- Correlation QQQ
- 0.21
Valuation details
MV $18.27
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 1 of 5
ValuationP/E of 0.9× vs a 28.9× median for the 161 Health Care companies we cover.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$120M over the last 12 months), so there’s no cash-flow value under the price.
ValuationFree-cash-flow yield of −10.0%, below the 1.9% median for the 303 Health Care companies we cover.
QualityDoesn’t pass our quality screen: no positive free cash flow; no return-on-capital data; no sales-growth data.
ValuationTrades 5.4% above its Market Value of $18.27, the average price paid since the Mar 27 filing.
RiskSwings hard: beta 1.76 vs the S&P 500 and 106% yearly volatility (SPY 13%).
All fundamentals
P/E 0.9 · FCF yield -10.0%
Valuation
- P/E
- 0.9×Health Care median 28.9×
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −10.0%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- n/anot reported in its SEC filings
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $1.2Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- n/anot reported in its SEC filings
- Sales growth, 12 months
- n/ano year-ago 12-month revenue
- Sales growth, 3 yrs
- n/anot reported in its SEC filings
- Diluted EPS, 12 months
- $300.56
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $1.4B
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- n/anot reported in its SEC filings
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- n/anegative shareholder equity
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $482M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$120M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- n/ano dividend payments tagged
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- $35M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From Vor Biopharma’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.1B
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield-10.0%
- Gross margin0%
- Operating margin0%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $19.25
- 52-wk lowlowest close, 1 year$6.86−64.4%
- Market Valueavg paid since Mar 27$18.27−5.1%
- PriceMon Nov 2 close$19.25you are here
- 52-wk highhighest close, 1 year$25.10+30.4%
Momentum & 52-week range
RSI 48 · 5 days +5.0%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
VOR is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Vor Biopharma in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Biotech
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.